Obesity Market Could Add Two New Therapies In The Near Term, Pfizer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The obesity drug market could potentially see two new entrants in the near term, Pfizer VP-U.S. Cardiovascular Medical Group Gary Palmer, MD, said Dec. 1 at the Health Care Research & Innovations Congress in Washington, D.C